Skip to content

BoxX-NoAF Clinical Trial

EnCompass Clamp and the AtriClip in Box Lesion and Left Atrial Appendage EXclusion Procedure for the Prevention of New Onset of Atrial Fibrillation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06989775
Enrollment
960
Registered
2025-05-25
Start date
2025-10-24
Completion date
2029-12-01
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Postoperative, Post Operative Atrial Fibrillation

Keywords

Post operative AF, Clinical AF

Brief summary

Post Operative Atrial Fibrillation (POAF) is the most common complication of cardiac surgery. POAF incidence can exceed 50% depending on the patient baseline characteristics and surgery type. Patients with POAF tend to have worse acute and long-term clinical outcomes. BoxX-NoAF is a randomized trial to evaluate if prophylactic ablation and exclusion of the Left Atrial Appendage at the time of other routine cardiac surgery can reduce the incidence of post operative AF and clinical AF during long term follow up in patients who have not yet developed AF but are at risk.

Interventions

DEVICEIsolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System

Box lesion ablation with the Isolator Synergy EnCompass Clamp System and LAAE using the AtriClip LAA Exclusion System at the time of planned cardiac surgery

Sponsors

AtriCure, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Planned and clinically indicated for cardiac surgical procedure requiring cardiac bypass and opening of the pericardium * Age ≥ 65 years and CHA2DS2-VASc ≥ 3

Exclusion criteria

* Documented history of atrial fibrillation or atrial flutter anytime prior to the cardiac surgery * Prior procedure involving opening the pericardium or entering the pericardial space * Patients undergoing off-pump surgery * Prior LAA occlusion, exclusion, or removal (surgical or percutaneous) * Presence of a permanent pacemaker * Infiltrative cardiomyopathies (i.e. amyloidosis) * Planned cardiac surgical procedure using non-sternotomy approaches * Patients whose planned procedure is a heart transplant or implantation of any long-term ventricular assist devices * Presence of ventricular arrhythmia * Active endocarditis * NYHA Class IV heart failure symptoms * Preoperative need for an intra-aortic ballon pump or intravenous inotropes * Active systemic infection at the time of cardiac surgery requiring antibiotics * Known allergy to Nitinol or nickel sensitivity * Known medical condition with expected survival of less than 1 year * Other comorbidities that in the Investigator's opinion make the subject unsuitable candidate to complete the protocol required intervention or visits * Current enrollment in an investigation or trial or an investigational devices or investigational drug that would interfere with this trial * Mental impairment or other psychiatric conditions which may not allow the patient to understand the nature, significance, and scope of the trial. * Pregnancy * Known severe symptomatic carotid disease

Design outcomes

Primary

MeasureTime frameDescription
Primary Effectiveness Endpoint30 days post index cardiac surgical procedureThe occurrence of clinically relevant post operative AF (POAF)
Primary Safety Endpoint30 days post index cardiac surgical procedureThe composite of the following events: * All cause Mortality * Reoperation * Deep sternal wound infection * Permanent stroke * Prolonged ventilation * Renal failure * 30-day readmission * Atypical left atrial flutter * Phrenic nerve palsy * Major Bleeding

Secondary

MeasureTime frameDescription
Powered Secondary Effectiveness Endpoint3 years post index cardiac surgical procedureThe time to first occurrence of clinical atrial fibrillation from 30 days after index cardiac surgical procedure through 3-years

Countries

Canada, United States

Contacts

CONTACTBoxX-NoAF Trial Inbox
BoxXNoAF@atricure.com1 (513) 755-4100

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 30, 2026